benralizumab (Fasenra)
benralizumab is an FDA-licensed reference biologic from AstraZeneca AB. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2019
Reference approved
Reference product
Fasenra benralizumab
AstraZeneca AB
- Approved
- Oct 03, 2019
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for benralizumab, in chronological order.
Reference approval
Approval date of the reference benralizumab product.
6 yr 9 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 5 yr 4 mo
Frequently asked questions
Are there biosimilars approved for benralizumab (Fasenra)?
No 351(k) biosimilars or interchangeable biosimilars referencing benralizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.